CRSP · CRISPR Therapeutics AG

CRISPR Therapeutics reported first quarter 2026 financial results, highlighting continued commercial momentum for CASGEVY and progress across its pipeline. CASGEVY generated $43 million in revenue, with over 500 patients having initiated the treatment journey globally. The company's cash position strengthened to $2,441.8 million as of March 31, 2026, up from $1,975.8 million at year-end 2025, primarily due to $585.4 million in net proceeds from convertible senior notes issued in March 2026. R&D expenses decreased to $68.6 million from $72.5 million in the prior year quarter, driven by lower employee-related costs. G&A expenses also declined to $17.2 million from $19.3 million. Collaboration expense, net, decreased to $45.9 million from $57.5 million, reflecting an increase in CRISPR's share of CASGEVY revenue. Net loss improved to $122.9 million from $136.0 million in Q1 2025. Management highlighted key pipeline milestones: zugo-cel advanced into new autoimmune indications with FDA clearance for a neurologic disease trial; in vivo liver programs CTX460 (AATD) and CTX340 (hypertension) are expected to enter the clinic in mid-2026 and first half of 2026, respectively; and CTX611 (siRNA) is in Phase 2 with an update expected in H2 2026. The company believes 2026 will be a defining year given its strengthened balance sheet and multiple upcoming milestones.